• Waters Corporation reported past first-quarter 2026 results with sales rising to US$1,267 million from US$662 million a year earlier, but swinging from net income of US$121 million to a net loss of US$72 million, with basic and diluted loss per share of US$0.87 from continuing operations.
• Alongside these results, Waters issued new guidance calling for very large second-quarter 2026 revenue of US$1.62 billion to US$1.63 billion and full-year 2026 revenue of US$6.41 billion to US$6.46 billion, underlining management’s confidence that recent BD Biosciences and Diagnostic Solutions acquisitions and organic growth can support stronger adjusted earnings.
• Next, we’ll examine how Waters’ strong adjusted earnings and raised 2026 revenue guidance reshape the existing investment narrative around growth and risk.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Waters Investment Narrative Recap

To own Waters today, you have to believe the enlarged company can turn its BD Biosciences and Diagnostic Solutions acquisitions plus its core analytical instruments into durable, higher quality earnings, without letting integration costs or weak end markets overwhelm the story. The latest quarter reinforces that the main short term catalyst is successful integration and synergy delivery, while the biggest risk remains that these large deals fail to translate into the earnings power implied by management’s targets.

The most relevant update here is Waters’ fresh 2026 revenue guidance of US$6.41 billion to US$6.46 billion, which broadly aligns with the company’s earlier full year outlook and frames the integration story in hard numbers. This guidance gives investors a reference point to judge whether early contributions from BD Biosciences and Diagnostic Solutions are translating into the stronger adjusted results that management has highlighted, and whether that potential is enough to justify the current valuation against the evident integration and margin risks.

Yet behind the strong guidance, investors should be aware that integration risk around the BD businesses could still...

Waters’ narrative projects $7.5 billion revenue and $1.4 billion earnings by 2029. This implies an earnings increase from today’s level to reach that $1.4 billion consensus by 2029.

Uncover how Waters' forecasts yield a $393.14 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming about US$7.6 billion revenue and US$1.4 billion earnings by 2029, and their more pessimistic focus on integration setbacks and margin pressure offers a useful counterweight that could shift meaningfully in light of these surprisingly mixed Q1 results.

Explore 3 other fair value estimates on Waters - why the stock might be worth as much as 34% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Waters research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Waters research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Waters' overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.